{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:51:16Z","timestamp":1792785076800,"version":"4.5.0"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T00:00:00Z","timestamp":1781568000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:00:00Z","timestamp":1790899200000},"content-version":"vor","delay-in-days":108,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100007849","name":"Respiratory Health Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007849","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002590","name":"American Lung Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002590","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007038","name":"Lung Cancer Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002192","name":"LUNGevity Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002192","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Novellia"},{"name":"Robert Winn Career Development","id":[{"id":"https:\/\/ror.org\/02xjhr934","id-type":"ROR","asserted-by":"crossref"}]},{"name":"NIH\/NCI"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Precis. Onc."],"DOI":"10.1038\/s41698-026-01559-y","type":"journal-article","created":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T15:55:54Z","timestamp":1781625354000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Patient-derived three-dimensional lung tumor models to evaluate response to therapy"],"prefix":"10.1038","volume":"10","author":[{"given":"Kayla F.","family":"Goliwas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aakash","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth P.","family":"Hough","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sruti","family":"Sivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sierra L.","family":"Single","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nithya","family":"Puritipati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aroma G.","family":"Tom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanad","family":"Alhushki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sameer S.","family":"Deshmukh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel L.","family":"Berry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maya","family":"Khalil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanis","family":"Boumber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Athar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selvarangan","family":"Ponnazhagan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James M.","family":"Donahue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessy S.","family":"Deshane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,16]]},"reference":[{"key":"1559_CR1","first-page":"12","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel, R. L., Giaquinto, A. N. & Jemal, A. Cancer statistics, 2024. CA Cancer J. Clin. 74, 12\u201349 (2024).","journal-title":"CA Cancer J. Clin."},{"key":"1559_CR2","doi-asserted-by":"publisher","unstructured":"Dong, J., Li, B., Lin, D., Zhou, Q. & Huang, D. Advances in targeted therapy and immunotherapy for non-small cell lung cancer based on accurate molecular typing. Front. Pharmacol. https:\/\/doi.org\/10.3389\/fphar.2019.00230 (2019).","DOI":"10.3389\/fphar.2019.00230"},{"key":"1559_CR3","unstructured":"Mittal, V. et al. In Lung Cancer and Personalized Medicine: Novel Therapies and Clinical Management (eds Ahmad, A. & Gadgeel, S. M.) 75\u2013110 (Springer International Publishing, 2016)."},{"key":"1559_CR4","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.cell.2017.01.018","volume":"168","author":"N McGranahan","year":"2017","unstructured":"McGranahan, N. & Swanton, C. Clonal heterogeneity and tumor evolution: past, present, and the future. Cell 168, 613\u2013628 (2017).","journal-title":"Cell"},{"key":"1559_CR5","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1007\/s40610-017-0073-7","volume":"3","author":"F Runa","year":"2017","unstructured":"Runa, F. et al. Tumor microenvironment heterogeneity: challenges and opportunities. Curr. Mol. Biol. Rep. 3, 218\u2013229 (2017).","journal-title":"Curr. Mol. Biol. Rep."},{"key":"1559_CR6","doi-asserted-by":"publisher","first-page":"18708","DOI":"10.1073\/pnas.1111840108","volume":"108","author":"J-P Gillet","year":"2011","unstructured":"Gillet, J.-P. et al. Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance. Proc. Natl. Acad. Sci. USA 108, 18708\u201318713 (2011).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"1559_CR7","doi-asserted-by":"publisher","unstructured":"Hynds, R. E., Vladimirou, E. & Janes, S. M. The secret lives of cancer cell lines. Dis. Model. Mech. https:\/\/doi.org\/10.1242\/dmm.037366 (2018).","DOI":"10.1242\/dmm.037366"},{"key":"1559_CR8","doi-asserted-by":"publisher","unstructured":"Arnal-Estape, A., Foggetti, G., Starrett, J. H., Nguyen, D. X. & Politi, K. Preclinical models for the study of lung cancer pathogenesis and therapy development. Cold Spring Harb. Perspect. Med. https:\/\/doi.org\/10.1101\/cshperspect.a037820 (2021).","DOI":"10.1101\/cshperspect.a037820"},{"key":"1559_CR9","doi-asserted-by":"publisher","first-page":"2595","DOI":"10.1093\/annonc\/mdx416","volume":"28","author":"E Izumchenko","year":"2017","unstructured":"Izumchenko, E. et al. Patient-derived xenografts effectively capture responses to oncology therapy in a heterogeneous cohort of patients with solid tumors. Ann. Oncol. 28, 2595\u20132605 (2017).","journal-title":"Ann. Oncol."},{"key":"1559_CR10","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1002\/path.1936","volume":"208","author":"D Guenot","year":"2006","unstructured":"Guenot, D. et al. Primary tumour genetic alterations and intra-tumoral heterogeneity are maintained in xenografts of human colon cancers showing chromosome instability. J. Pathol. 208, 643\u2013652 (2006).","journal-title":"J. Pathol."},{"key":"1559_CR11","doi-asserted-by":"publisher","first-page":"5315","DOI":"10.1158\/0008-5472.CAN-13-1069","volume":"73","author":"D Siolas","year":"2013","unstructured":"Siolas, D. & Hannon, G. J. Patient-derived tumor xenografts: transforming clinical samples into mouse models. Cancer Res. 73, 5315\u20135319 (2013).","journal-title":"Cancer Res."},{"key":"1559_CR12","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/nrclinonc.2012.61","volume":"9","author":"JJ Tentler","year":"2012","unstructured":"Tentler, J. J. et al. Patient-derived tumour xenografts as models for oncology drug development. Nat. Rev. Clin. Oncol. 9, 338\u2013350 (2012).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1559_CR13","doi-asserted-by":"publisher","first-page":"2","DOI":"10.3389\/fonc.2017.00002","volume":"7","author":"KM Morgan","year":"2017","unstructured":"Morgan, K. M., Riedlinger, G. M., Rosenfeld, J., Ganesan, S. & Pine, S. R. Patient-derived xenograft models of non-small cell lung cancer and their potential utility in personalized medicine. Front Oncol. 7, 2 (2017).","journal-title":"Front Oncol."},{"key":"1559_CR14","doi-asserted-by":"publisher","first-page":"568567","DOI":"10.1155\/2012\/568567","volume":"2012","author":"M Moro","year":"2012","unstructured":"Moro, M. et al. Patient-derived xenografts of non small cell lung cancer: resurgence of an old model for investigation of modern concepts of tailored therapy and cancer stem cells. J. Biomed. Biotechnol. 2012, 568567 (2012).","journal-title":"J. Biomed. Biotechnol."},{"key":"1559_CR15","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s13045-019-0829-z","volume":"13","author":"GJ Yoshida","year":"2020","unstructured":"Yoshida, G. J. Applications of patient-derived tumor xenograft models and tumor organoids. J. Hematol. Oncol. 13, 4 (2020).","journal-title":"J. Hematol. Oncol."},{"key":"1559_CR16","doi-asserted-by":"publisher","first-page":"e0160587","DOI":"10.1371\/journal.pone.0160587","volume":"11","author":"VE Schneeberger","year":"2016","unstructured":"Schneeberger, V. E., Allaj, V., Gardner, E. E., Poirier, J. T. & Rudin, C. M. Quantitation of murine stroma and selective purification of the human tumor component of patient-derived xenografts for genomic analysis. PLoS ONE 11, e0160587 (2016).","journal-title":"PLoS ONE"},{"key":"1559_CR17","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/s41563-021-01057-5","volume":"21","author":"BL LeSavage","year":"2022","unstructured":"LeSavage, B. L., Suhar, R. A., Broguiere, N., Lutolf, M. P. & Heilshorn, S. C. Next-generation cancer organoids. Nat. Mater. 21, 143\u2013159 (2022).","journal-title":"Nat. Mater."},{"key":"1559_CR18","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/s43018-020-0102-y","volume":"1","author":"Y-H Lo","year":"2020","unstructured":"Lo, Y.-H., Karlsson, K. & Kuo, C. J. Applications of organoids for cancer biology and precision medicine. Nat. Cancer 1, 761\u2013773 (2020).","journal-title":"Nat. Cancer"},{"key":"1559_CR19","doi-asserted-by":"publisher","first-page":"eaaz1723","DOI":"10.1126\/scitranslmed.aaz1723","volume":"12","author":"S Yin","year":"2020","unstructured":"Yin, S. et al. Patient-derived tumor-like cell clusters for drug testing in cancer therapy. Sci. Transl. Med. 12, eaaz1723 (2020).","journal-title":"Sci. Transl. Med."},{"key":"1559_CR20","doi-asserted-by":"publisher","first-page":"103610","DOI":"10.1016\/j.critrevonc.2022.103610","volume":"171","author":"H-c Ma","year":"2022","unstructured":"Ma, H. -c et al. Lung cancer organoids, a promising model still with long way to go. Crit. Rev. Oncol.\/Hematol. 171, 103610 (2022).","journal-title":"Crit. Rev. Oncol.\/Hematol."},{"key":"1559_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-11867-6","volume":"10","author":"M Kim","year":"2019","unstructured":"Kim, M. et al. Patient-derived lung cancer organoids as in vitro cancer models for therapeutic screening. Nat. Commun. 10, 3991 (2019).","journal-title":"Nat. Commun."},{"key":"1559_CR22","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1158\/1078-0432.CCR-19-1376","volume":"26","author":"R Shi","year":"2020","unstructured":"Shi, R. et al. Organoid cultures as preclinical models of non-small cell lung cancer. Clin. Cancer Res. 26, 1162\u20131174 (2020).","journal-title":"Clin. Cancer Res."},{"key":"1559_CR23","doi-asserted-by":"publisher","first-page":"107533","DOI":"10.1016\/j.lungcan.2024.107533","volume":"190","author":"JA Taverna","year":"2024","unstructured":"Taverna, J. A. et al. Ex vivo drug testing of patient-derived lung organoids to predict treatment responses for personalized medicine. Lung Cancer 190, 107533 (2024).","journal-title":"Lung Cancer"},{"key":"1559_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-023-01332-9","volume":"21","author":"H Li","year":"2023","unstructured":"Li, H. et al. Applications of lung cancer organoids in precision medicine: from bench to bedside. Cell Commun. Signal 21, 350 (2023).","journal-title":"Cell Commun. Signal"},{"key":"1559_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-47737-z","volume":"15","author":"Y Zhang","year":"2024","unstructured":"Zhang, Y. et al. A patient-specific lung cancer assembloid model with heterogeneous tumor microenvironments. Nat. Commun. 15, 3382 (2024).","journal-title":"Nat. Commun."},{"key":"1559_CR26","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.celrep.2017.09.043","volume":"21","author":"BA Hassell","year":"2017","unstructured":"Hassell, B. A. et al. Human organ chip models recapitulate orthotopic lung cancer growth, therapeutic responses, and tumor dormancy in vitro. Cell Rep. 21, 508\u2013516 (2017).","journal-title":"Cell Rep."},{"key":"1559_CR27","doi-asserted-by":"publisher","unstructured":"Ahmad, S. et al. Heavy metal exposure-mediated dysregulation of sphingolipid metabolism. Antioxidants https:\/\/doi.org\/10.3390\/antiox13080978 (2024).","DOI":"10.3390\/antiox13080978"},{"key":"1559_CR28","doi-asserted-by":"publisher","first-page":"654922","DOI":"10.3389\/fonc.2021.654922","volume":"11","author":"KF Goliwas","year":"2021","unstructured":"Goliwas, K. F. et al. Extracellular vesicle mediated tumor-stromal crosstalk within an engineered lung cancer model. Front Oncol. 11, 654922 (2021).","journal-title":"Front Oncol."},{"key":"1559_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-14326-8","volume":"7","author":"KF Goliwas","year":"2017","unstructured":"Goliwas, K. F. et al. Methods to evaluate cell growth, viability, and response to treatment in a tissue engineered breast cancer model. Sci. Rep. 7, 14167 (2017).","journal-title":"Sci. Rep."},{"key":"1559_CR30","doi-asserted-by":"publisher","unstructured":"Goliwas, K. F. et al. Local SARS-CoV-2 peptide-specific immune responses in lungs of convalescent and uninfected human subjects. medRxiv https:\/\/doi.org\/10.1101\/2021.09.02.21263042 (2022).","DOI":"10.1101\/2021.09.02.21263042"},{"key":"1559_CR31","doi-asserted-by":"publisher","first-page":"710009","DOI":"10.3389\/fendo.2021.710009","volume":"12","author":"B Herring","year":"2021","unstructured":"Herring, B. et al. Ex vivo modeling of human neuroendocrine tumors in tissue surrogates. Front Endocrinol. 12, 710009 (2021).","journal-title":"Front Endocrinol."},{"key":"1559_CR32","doi-asserted-by":"publisher","first-page":"2930","DOI":"10.1172\/JCI91190","volume":"127","author":"M Ayers","year":"2017","unstructured":"Ayers, M. et al. IFN-\u03b3\u2013related mRNA profile predicts clinical response to PD-1 blockade. J. Clin. Investig. 127, 2930\u20132940 (2017).","journal-title":"J. Clin. Investig."},{"key":"1559_CR33","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-019-2100-3","volume":"17","author":"D Damotte","year":"2019","unstructured":"Damotte, D. et al. The tumor inflammation signature (TIS) is associated with anti-PD-1 treatment benefit in the CERTIM pan-cancer cohort. J. Transl. Med. 17, 357 (2019).","journal-title":"J. Transl. Med."},{"key":"1559_CR34","doi-asserted-by":"publisher","unstructured":"Huang, Y. et al. Factors predictive of primary resistance to immune checkpoint inhibitors in patients with advanced non-small cell lung cancer. Cancers https:\/\/doi.org\/10.3390\/cancers15102733 (2023).","DOI":"10.3390\/cancers15102733"},{"key":"1559_CR35","doi-asserted-by":"publisher","first-page":"1129465","DOI":"10.3389\/fimmu.2023.1129465","volume":"14","author":"S Zhou","year":"2023","unstructured":"Zhou, S. & Yang, H. Immunotherapy resistance in non-small-cell lung cancer: from mechanism to clinical strategies. Front Immunol. 14, 1129465 (2023).","journal-title":"Front Immunol."},{"key":"1559_CR36","doi-asserted-by":"publisher","first-page":"2415","DOI":"10.1056\/NEJMoa1613493","volume":"376","author":"DP Carbone","year":"2017","unstructured":"Carbone, D. P. et al. First-line nivolumab in stage iv or recurrent non-small-cell lung cancer. N. Engl. J. Med. 376, 2415\u20132426 (2017).","journal-title":"N. Engl. J. Med."},{"key":"1559_CR37","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","volume":"381","author":"MD Hellmann","year":"2019","unstructured":"Hellmann, M. D. et al. Nivolumab plus ipilimumab in advanced non-small-cell lung cancer. N. Engl. J. Med. 381, 2020\u20132031 (2019).","journal-title":"N. Engl. J. Med."},{"key":"1559_CR38","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","volume":"393","author":"TSK Mok","year":"2019","unstructured":"Mok, T. S. K. et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet 393, 1819\u20131830 (2019).","journal-title":"Lancet"},{"key":"1559_CR39","doi-asserted-by":"publisher","unstructured":"Kluger, H. et al. Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors. J. Immunother. Cancer https:\/\/doi.org\/10.1136\/jitc-2022-005921 (2023).","DOI":"10.1136\/jitc-2022-005921"},{"key":"1559_CR40","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1093\/intimm\/dxw019","volume":"28","author":"N Riaz","year":"2016","unstructured":"Riaz, N. et al. The role of neoantigens in response to immune checkpoint blockade. Int Immunol. 28, 411\u2013419 (2016).","journal-title":"Int Immunol."},{"key":"1559_CR41","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1158\/2159-8290.CD-15-0283","volume":"6","author":"W Peng","year":"2016","unstructured":"Peng, W. et al. Loss of PTEN promotes resistance to T cell-mediated immunotherapy. Cancer Discov. 6, 202\u2013216 (2016).","journal-title":"Cancer Discov."},{"key":"1559_CR42","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s00262-013-1508-5","volume":"63","author":"C Meyer","year":"2014","unstructured":"Meyer, C. et al. Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab. Cancer Immunol. Immunother. 63, 247\u2013257 (2014).","journal-title":"Cancer Immunol. Immunother."},{"key":"1559_CR43","doi-asserted-by":"publisher","first-page":"932","DOI":"10.4049\/jimmunol.173.2.932","volume":"173","author":"H Zhang","year":"2004","unstructured":"Zhang, H. et al. Adenosine acts through A2 receptors to inhibit IL-2-induced tyrosine phosphorylation of STAT5 in T lymphocytes: role of cyclic adenosine 3\u2019,5\u2019-monophosphate and phosphatases. J. Immunol. 173, 932\u2013944 (2004).","journal-title":"J. Immunol."},{"key":"1559_CR44","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-018-1595-3","volume":"16","author":"A Botticelli","year":"2018","unstructured":"Botticelli, A. et al. Can IDO activity predict primary resistance to anti-PD-1 treatment in NSCLC? J. Transl. Med. 16, 219 (2018).","journal-title":"J. Transl. Med."},{"key":"1559_CR45","doi-asserted-by":"publisher","first-page":"216824","DOI":"10.1016\/j.canlet.2024.216824","volume":"589","author":"T Yu","year":"2024","unstructured":"Yu, T. et al. Targeting tumor-intrinsic SLC16A3 to enhance anti-PD-1 efficacy via tumor immune microenvironment reprogramming. Cancer Lett. 589, 216824 (2024).","journal-title":"Cancer Lett."},{"key":"1559_CR46","doi-asserted-by":"publisher","first-page":"eabn6173","DOI":"10.1126\/sciimmunol.abn6173","volume":"8","author":"M van Gulijk","year":"2023","unstructured":"van Gulijk, M. et al. PD-L1 checkpoint blockade promotes regulatory T cell activity that underlies therapy resistance. Sci. Immunol. 8, eabn6173 (2023).","journal-title":"Sci. Immunol."},{"key":"1559_CR47","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1002\/cac2.12327","volume":"42","author":"C Liu","year":"2022","unstructured":"Liu, C. et al. KRAS-G12D mutation drives immune suppression and the primary resistance of anti-PD-1\/PD-L1 immunotherapy in non-small cell lung cancer. Cancer Commun. 42, 828\u2013847 (2022).","journal-title":"Cancer Commun."},{"key":"1559_CR48","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1158\/1078-0432.CCR-23-2566","volume":"30","author":"A Bessede","year":"2024","unstructured":"Bessede, A. et al. TROP2 is associated with primary resistance to immune checkpoint inhibition in patients with advanced non\u2013small cell lung cancer. Clin. Cancer Res. 30, 779\u2013785 (2024).","journal-title":"Clin. Cancer Res."},{"key":"1559_CR49","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/nature14011","volume":"515","author":"RS Herbst","year":"2014","unstructured":"Herbst, R. S. et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515, 563\u2013567 (2014).","journal-title":"Nature"},{"key":"1559_CR50","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1038\/s41591-018-0057-z","volume":"24","author":"DS Thommen","year":"2018","unstructured":"Thommen, D. S. et al. A transcriptionally and functionally distinct PD-1(+) CD8(+) T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade. Nat. Med. 24, 994\u20131004 (2018).","journal-title":"Nat. Med."},{"key":"1559_CR51","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-023-00428-2","volume":"7","author":"JM Romero","year":"2023","unstructured":"Romero, J. M. et al. Chemokine expression predicts T cell-inflammation and improved survival with checkpoint inhibition across solid cancers. npj Precis. Oncol. 7, 73 (2023).","journal-title":"npj Precis. Oncol."},{"key":"1559_CR52","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/j.jtho.2018.03.008","volume":"13","author":"SN Gettinger","year":"2018","unstructured":"Gettinger, S. N. et al. Clinical features and management of acquired resistance to PD-1 axis inhibitors in 26 patients with advanced non-small cell lung cancer. J. Thorac. Oncol. 13, 831\u2013839 (2018).","journal-title":"J. Thorac. Oncol."},{"key":"1559_CR53","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.ccell.2020.03.017","volume":"37","author":"AJ Schoenfeld","year":"2020","unstructured":"Schoenfeld, A. J. & Hellmann, M. D. Acquired resistance to immune checkpoint inhibitors. Cancer Cell 37, 443\u2013455 (2020).","journal-title":"Cancer Cell"},{"key":"1559_CR54","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.ccell.2023.12.013","volume":"42","author":"D Memon","year":"2024","unstructured":"Memon, D. et al. Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer. Cancer Cell 42, 209\u2013224.e209 (2024).","journal-title":"Cancer Cell"},{"key":"1559_CR55","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1200\/JCO.23.00580","volume":"42","author":"B Ricciuti","year":"2024","unstructured":"Ricciuti, B. et al. Genomic and immunophenotypic landscape of acquired resistance to PD-(L)1 blockade in non-small-cell lung cancer. J. Clin. Oncol. 42, 1311\u20131321 (2024).","journal-title":"J. Clin. Oncol."},{"key":"1559_CR56","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1158\/2159-8290.CD-17-0593","volume":"7","author":"S Gettinger","year":"2017","unstructured":"Gettinger, S. et al. Impaired HLA Class I antigen processing and presentation as a mechanism of acquired resistance to immune checkpoint inhibitors in lung cancer. Cancer Discov. 7, 1420\u20131435 (2017).","journal-title":"Cancer Discov."},{"key":"1559_CR57","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1056\/NEJMoa1604958","volume":"375","author":"JM Zaretsky","year":"2016","unstructured":"Zaretsky, J. M. et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N. Engl. J. Med. 375, 819\u2013829 (2016).","journal-title":"N. Engl. J. Med."},{"key":"1559_CR58","doi-asserted-by":"publisher","unstructured":"Robles-Oteiza, C. et al. Hypoxia is linked to acquired resistance to immune checkpoint inhibitors in lung cancer. J. Exp. Med. https:\/\/doi.org\/10.1084\/jem.20231106 (2025).","DOI":"10.1084\/jem.20231106"},{"key":"1559_CR59","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-40745-5","volume":"14","author":"S Hiltbrunner","year":"2023","unstructured":"Hiltbrunner, S. et al. Acquired resistance to anti-PD1 therapy in patients with NSCLC associates with immunosuppressive T cell phenotype. Nat. Commun. 14, 5154 (2023).","journal-title":"Nat. Commun."},{"key":"1559_CR60","doi-asserted-by":"publisher","first-page":"684098","DOI":"10.3389\/fonc.2021.684098","volume":"11","author":"DR Principe","year":"2021","unstructured":"Principe, D. R., Chiec, L., Mohindra, N. A. & Munshi, H. G. Regulatory T-cells as an emerging barrier to immune checkpoint inhibition in lung cancer. Front Oncol. 11, 684098 (2021).","journal-title":"Front Oncol."},{"key":"1559_CR61","first-page":"A630","volume":"11","author":"S Miao","year":"2023","unstructured":"Miao, S., Leticia Rodriguez, B., Konen, J. M., Tian, Y. & Gibbons, D. 552 Tumor-infiltrating neutrophils associate with resistance to anti-PD1 immunotherapy in NSCLC. J. Immunother. Cancer 11, A630\u2013A630 (2023).","journal-title":"J. Immunother. Cancer"},{"key":"1559_CR62","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/bjc.2017.434","volume":"118","author":"RW Jenkins","year":"2018","unstructured":"Jenkins, R. W., Barbie, D. A. & Flaherty, K. T. Mechanisms of resistance to immune checkpoint inhibitors. Br. J. Cancer 118, 9\u201316 (2018).","journal-title":"Br. J. Cancer"},{"key":"1559_CR63","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1158\/2326-6066.CIR-20-0586","volume":"10","author":"M Karasarides","year":"2022","unstructured":"Karasarides, M. et al. Hallmarks of resistance to immune-checkpoint inhibitors. Cancer Immunol. Res. 10, 372\u2013383 (2022).","journal-title":"Cancer Immunol. Res."},{"key":"1559_CR64","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-20935-9","volume":"12","author":"C Valero","year":"2021","unstructured":"Valero, C. et al. Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors. Nat. Commun. 12, 729 (2021).","journal-title":"Nat. Commun."},{"key":"1559_CR65","doi-asserted-by":"publisher","unstructured":"Kargl, J. et al. Neutrophil content predicts lymphocyte depletion and anti-PD1 treatment failure in NSCLC. JCI Insight https:\/\/doi.org\/10.1172\/jci.insight.130850 (2019).","DOI":"10.1172\/jci.insight.130850"},{"key":"1559_CR66","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.cellimm.2004.09.004","volume":"230","author":"G Cai","year":"2004","unstructured":"Cai, G. et al. PD-1 ligands, negative regulators for activation of naive, memory, and recently activated human CD4+ T cells. Cell Immunol. 230, 89\u201398 (2004).","journal-title":"Cell Immunol."},{"key":"1559_CR67","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.4049\/jimmunol.170.3.1257","volume":"170","author":"JA Brown","year":"2003","unstructured":"Brown, J. A. et al. Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production. J. Immunol. 170, 1257\u20131266 (2003).","journal-title":"J. Immunol."},{"key":"1559_CR68","doi-asserted-by":"publisher","first-page":"5789","DOI":"10.4049\/jimmunol.1402180","volume":"194","author":"V Tkachev","year":"2015","unstructured":"Tkachev, V. et al. Programmed death-1 controls T cell survival by regulating oxidative metabolism. J. Immunol. 194, 5789\u20135800 (2015).","journal-title":"J. Immunol."},{"key":"1559_CR69","doi-asserted-by":"publisher","first-page":"e44728","DOI":"10.1371\/journal.pone.0044728","volume":"7","author":"A Singh","year":"2012","unstructured":"Singh, A., Dey, A. B., Mohan, A., Sharma, P. K. & Mitra, D. K. Foxp3+ regulatory T cells among tuberculosis patients: impact on prognosis and restoration of antigen specific IFN-\u03b3 producing T cells. PLoS ONE 7, e44728 (2012).","journal-title":"PLoS ONE"},{"key":"1559_CR70","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/gt.2014.104","volume":"22","author":"T Tsukahara","year":"2015","unstructured":"Tsukahara, T. et al. The Tol2 transposon system mediates the genetic engineering of T-cells with CD19-specific chimeric antigen receptors for B-cell malignancies. Gene Ther. 22, 209\u2013215 (2015).","journal-title":"Gene Ther."},{"key":"1559_CR71","doi-asserted-by":"publisher","unstructured":"Naba, A., Clauser, K. R. & Hynes, R. O. Enrichment of extracellular matrix proteins from tissues and digestion into peptides for mass spectrometry analysis. J. Vis. Exp. https:\/\/doi.org\/10.3791\/53057 (2015).","DOI":"10.3791\/53057"},{"key":"1559_CR72","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-28020-5","volume":"13","author":"P Danaher","year":"2022","unstructured":"Danaher, P. et al. Advances in mixed cell deconvolution enable quantification of cell types in spatial transcriptomic data. Nat. Commun. 13, 385 (2022).","journal-title":"Nat. Commun."}],"container-title":["npj Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01559-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01559-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01559-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:03:29Z","timestamp":1790899409000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01559-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,16]]},"references-count":72,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1559"],"URL":"https:\/\/doi.org\/10.1038\/s41698-026-01559-y","relation":{},"ISSN":["2397-768X"],"issn-type":[{"value":"2397-768X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,16]]},"assertion":[{"value":"20 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.S.D and K.F.G. are equal partners within Dynamic Tissue Mimics LLC, however, the work presented is independent of this interest. There is currently no financial interest associated with this interest. A.D has Consulting\/Advisory Roles at: Sanofi, Amgen, Foundation Medicine, AstraZeneca, Janssen Oncology, Merus, AbbVie, Catalyst Pharmaceuticals, Merck, Eli Lilly, Daiichi Sankyo, and Regeneron. All other authors declare no potential conflicts of interest with respect to the research, authorship, and\/or publication of this article.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"366"}}